CTC Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The report covers Circulating Tumor Cell Market Companies and the market is Segmented by Device Type (Central Vascular Access Devices (Peripherally Inserted, Central Catheters, Percutaneous Non-tunneled Catheters, Other Central Vascular Access Devices) and Peripheral Vascular Access Devices (Peripheral Catheter, Midline Catheter, Other Peripheral Vascular Access Devices), Application (Administration of Drugs Administration of Fluid and Nutrition, Diagnostics and Testing, Other Applications) End-User (Hospital/Clinic, Diagnostic Centers, Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The market provides the value (in USD million) for the above-mentioned segments.

CTC Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Circulating Tumor Cells (CTC) Market Size

Circulating Tumor Cells (CTC) Market Size
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 9.50 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Global Circulating Tumor Cells (CTC) Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Circulating Tumor Cells (CTC) Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Circulating Tumor Cells (CTC) Market Analysis

The Global Circulating Tumor Cells Market is expected to register a CAGR of 9.5% during the forecast period.

The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. For instance, a study titled "Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study" in September 2020 reported that a total of 356 centers from 54 countries across six continents participated between April 21 and May 8, 2020. These centers serve 716,979 new patients with cancer every year. Most of them (88.2%) reported facing challenges in delivering care during the pandemic. Although 55.34% reduced services as part of a preemptive strategy, other common reasons included an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), staff shortage (17.98%), and restricted access to medications (9.83%). Thus, this indicates that due to COVID-19, there were disruptions in cancer care regarding reduced chemotherapy and radiotherapy services and ongoing research and development studies, thereby impacting the market growth.

Additionally, the study "Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer," published in September 2021, evaluated the effect of COVID-19-induced lockdown on newly diagnosed colorectal cancer cases through circulating tumor DNA and reported that tumor burden in patients who received a diagnosis after the lockdown was significantly higher compared with those who were diagnosed before the lockdown. This study indicated that the tumor burden increased during COVID-19 significantly and thus dramatically impacted the market growth.

The major factors for the growth of the circulating tumor cells (CTC) market include the advancements in biomedical imaging and bioengineering technology; the rising demand for preventive medicine and companion diagnostics; and the growing prevalence of cancer.

The global cancer burden is increasing; thus, cancer therapies must be modified according to regional and national priorities. For instance, according to the September 2021 update by the World Health Organization (WHO), cancer accounted for approximately 10 million worldwide deaths in 2020. The most common in 2020 (in terms of new cases of cancer) were: breast (2.26 million cases); lung (2.21 million cases); colon and rectum (1.93 million cases); prostate (1.41 million cases); skin (non-melanoma) (1.20 million cases); and stomach (1.09 million cases).

In addition, as per the 2020 statistics by Globocan, 19,292,789 people were diagnosed with cancer in 2020. As per the same source mentioned above, the number of people with cancer is estimated to reach 30.2 million by 2040. The increasing cancer burden is due to several factors, such as population growth and aging and the changing prevalence of specific causes of cancer linked to social and economic development. For instance, as per the World Health Organization (WHO), in September 2021, about one-third of deaths from cancer are due to tobacco use, high body mass index, alcohol use, low fruit and vegetable intake, and lack of physical activity. Thus, increasing tobacco consumption is expected to cause an increase in the prevalence of cancer, thereby contributing to market growth.

Moreover, the positive results from the recent clinical studies in the market may also boost and lead to significant market growth in the future. For instance, a study titled "Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells in Patients With Advanced or Metastatic Tumors" was initiated in February 2021 to evaluate the ability of heat shock protein HSP70 to isolate and quantify circulating tumor cells (CTCs) in patients with advanced or metastatic tumors. 

Thus, owing to the factors above, the studied market is expected to grow significantly during the study period. However, technical difficulties in the detection and characterization of CTCs associated with the high cost of diagnosis, lack of awareness, and unwillingness to adopt advanced CTC technologies are expected to hamper the market's growth further.

Circulating Tumor Cells (CTC) Industry Overview

The market studied is a moderately consolidated market, owing to the presence of small and large market players. Some market players are Advanced Cell Diagnostics Inc., Aviva Biosciences, Biocept Inc., Creatv Micro Tech, Inc., LungLife AI Inc., Menarini Silicon Biosystems, and Miltenyi Biotec, Precision For Medicine (Formerly ApoCell), and Qiagen NV.

Circulating Tumor Cells (CTC) Market Leaders

  1. Menarini Silicon Biosystems

  2. Miltenyi Biotec

  3. Precision For Medicine (Formerly ApoCell)

  4. Qiagen NV

  5. Biocept Inc

  6. *Disclaimer: Major Players sorted in no particular order
 Advanced Cell Diagnostics Inc., Aviva Biosciences, Biocept Inc., Creatv Micro Tech, Inc., LungLife AI Inc., Menarini Silicon Biosystems, Miltenyi Biotec, Precision For Medicine (Formerly ApoCell), and Qiagen NV.
Need More Details on Market Players and Competiters?
Download PDF

Circulating Tumor Cells (CTC) Market News

  • In July 2021, Datar Cancer Genetics reported the publication of a MedTech Innovation Briefing (MIB) from the United Kingdom's National Institute for Health and Care Excellence (NICE) on its CE-marked 'Trueblood-Prostate' test to be used for precision triaging of patients to avoid unnecessary invasive biopsies.
  • In February 2021, Menarini Silicon Biosystems launched a CellMag product line for the manual enrichment and staining of rare circulating tumor cells (CTCs).

Circulating Tumor Cells (CTC) Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Advancements in Biomedical Imaging and Bioengineering Technology
    • 4.2.2 Rising Demand for Preventive Medicine and Companion Diagnostics
    • 4.2.3 Increasing Prevalence of Cancer
  • 4.3 Market Restraints
    • 4.3.1 Technical Difficulties in Detection and Characterization of CTCs Associated with High Cost of Diagnosis
    • 4.3.2 Lack of Awarness and Unwillingness for the Adoption of Advanced CTC Technologies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Technology
    • 5.1.1 CTC Enrichment Methods
    • 5.1.1.1 Positive Enrichment
    • 5.1.1.2 Negative Enrichment
    • 5.1.1.3 Other Technologies
    • 5.1.2 CTC Detection Methods
    • 5.1.2.1 Immunocytochemical Technology
    • 5.1.2.2 Molecular (RNA)-based Technology
    • 5.1.2.3 Other CTC Detection Methods
  • 5.2 By Application
    • 5.2.1 Multiple Chromosome Abnormalities
    • 5.2.2 RNA Profiling
    • 5.2.3 Protein Expression
    • 5.2.4 Cellular Communication
    • 5.2.5 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Advanced Cell Diagnostics Inc.
    • 6.1.2 Aviva Biosciences
    • 6.1.3 Biocept Inc.
    • 6.1.4 Creatv Micro Tech Inc.
    • 6.1.5 LungLife AI Inc.
    • 6.1.6 Menarini Silicon Biosystems
    • 6.1.7 Miltenyi Biotec
    • 6.1.8 Precision for Medicine (Formerly ApoCell)
    • 6.1.9 Qiagen NV
    • 6.1.10 BioChain Institute Inc.
    • 6.1.11 Thermofisher
    • 6.1.12 Sysmex Corporation
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Circulating Tumor Cells (CTC) Industry Segmentation

As per the scope of this report, circulating tumor cells (CTC) refer to the tumor cells that air inside the body through the blood circulatory system and lymphatic system. Factors such as the high prevalence of cancer, advancements in biomedical imaging and bioengineering technology, increased demand for preventive medicine, and the need for companion diagnostics drive the circulating tumor cells market globally. The Circulating Tumor Cells (CTC) Market is segmented by Technology (CTC Enrichment Methods and CTC Detection Methods), Application (Multiple Chromosal Abnormalities, RNA Profiling, Protein Expression, Cellular Communications, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.

By Technology CTC Enrichment Methods Positive Enrichment
Negative Enrichment
Other Technologies
By Technology CTC Detection Methods Immunocytochemical Technology
Molecular (RNA)-based Technology
Other CTC Detection Methods
By Application Multiple Chromosome Abnormalities
RNA Profiling
Protein Expression
Cellular Communication
Other Applications
Geography North America United States
Canada
Mexico
Geography Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Geography Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Geography Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
Geography South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Circulating Tumor Cells (CTC) Market Research FAQs

What is the current Global Circulating Tumor Cells (CTC) Market size?

The Global Circulating Tumor Cells (CTC) Market is projected to register a CAGR of 9.5% during the forecast period (2025-2030)

Who are the key players in Global Circulating Tumor Cells (CTC) Market?

Menarini Silicon Biosystems, Miltenyi Biotec, Precision For Medicine (Formerly ApoCell), Qiagen NV and Biocept Inc are the major companies operating in the Global Circulating Tumor Cells (CTC) Market.

Which is the fastest growing region in Global Circulating Tumor Cells (CTC) Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Circulating Tumor Cells (CTC) Market?

In 2025, the North America accounts for the largest market share in Global Circulating Tumor Cells (CTC) Market.

What years does this Global Circulating Tumor Cells (CTC) Market cover?

The report covers the Global Circulating Tumor Cells (CTC) Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Circulating Tumor Cells (CTC) Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

CTC Industry Report

Statistics for the 2025 Global Circulating Tumor Cells (CTC) market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Circulating Tumor Cells (CTC) analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

  翻译: